Abstract
This descriptive study used the Japanese spontaneous reporting data to investigate the time taken (TTILD) to development of interstitial lung disease (ILD) after initiation of chemotherapy and the death rates attributed in part to post-chemotherapy ILD (i.e., DR) for anticancer drugs. We evaluated TTILD and DR endpoints for 36 anticancer drugs, which are widely used for treating 11 solid and 3 hematological cancers, and are suspected of causing ILD, by using 8- year spontaneous reporting data recording for 2,553 patients in the reporting system of the relevant Japanese regulatory agency. The median TTILD and overall DR attributable to post-chemotherapy ILD for the drugs were 1.8 months and 29%, respectively. For most drugs, the median TTILDs were between 1 to 4 months, and the DRs attributable to postchemotherapy ILD were <40%; however, TTILDs were as long as 4 to 6 months and DRs attributable to postchemotherapy ILD were ≥40% for several other drugs. Of the 36 drugs, we identified those that may trigger postchemotherapy late-onset ILDs or result in high DRs. The anticancer drugs that may have triggered late-onset ILDs were defined as those that caused ILD development after approximately 4 months from the initial drug administration.
Keywords: Adverse drug-reaction reporting, anticancer drug, epidemiology, interstitial lung disease, post-marketing surveillance, spontaneous report.
Current Drug Safety
Title:A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan
Volume: 9 Issue: 3
Author(s): Akihiro Hirakawa, Kan Yonemori, Yachiyo Kuwatsuka, Makoto Kodaira, Harukaze Yamamoto, Mayu Yunokawa, Akinobu Hamada, Chikako Shimizu, Kenji Tamura, Akihiko Gemma and Yasuhiro Fujiwara
Affiliation:
Keywords: Adverse drug-reaction reporting, anticancer drug, epidemiology, interstitial lung disease, post-marketing surveillance, spontaneous report.
Abstract: This descriptive study used the Japanese spontaneous reporting data to investigate the time taken (TTILD) to development of interstitial lung disease (ILD) after initiation of chemotherapy and the death rates attributed in part to post-chemotherapy ILD (i.e., DR) for anticancer drugs. We evaluated TTILD and DR endpoints for 36 anticancer drugs, which are widely used for treating 11 solid and 3 hematological cancers, and are suspected of causing ILD, by using 8- year spontaneous reporting data recording for 2,553 patients in the reporting system of the relevant Japanese regulatory agency. The median TTILD and overall DR attributable to post-chemotherapy ILD for the drugs were 1.8 months and 29%, respectively. For most drugs, the median TTILDs were between 1 to 4 months, and the DRs attributable to postchemotherapy ILD were <40%; however, TTILDs were as long as 4 to 6 months and DRs attributable to postchemotherapy ILD were ≥40% for several other drugs. Of the 36 drugs, we identified those that may trigger postchemotherapy late-onset ILDs or result in high DRs. The anticancer drugs that may have triggered late-onset ILDs were defined as those that caused ILD development after approximately 4 months from the initial drug administration.
Export Options
About this article
Cite this article as:
Hirakawa Akihiro, Yonemori Kan, Kuwatsuka Yachiyo, Kodaira Makoto, Yamamoto Harukaze, Yunokawa Mayu, Hamada Akinobu, Shimizu Chikako, Tamura Kenji, Gemma Akihiko and Fujiwara Yasuhiro, A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan, Current Drug Safety 2014; 9 (3) . https://dx.doi.org/10.2174/1574886309666140601205940
DOI https://dx.doi.org/10.2174/1574886309666140601205940 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Withdrawn: Mesenchymal Stem Cell-derived Exosomes for Treatment of
Ischemic Stroke
Current Stem Cell Research & Therapy Defensive and Offensive Cross-Reactive Antibodies Elicited by Pathogens: The Good, the Bad and the Ugly
Current Medicinal Chemistry Nutritional Antioxidants and Adaptive Cell Responses: An Update
Current Molecular Medicine Tachykinins and the Cardiovascular System
Current Drug Targets Biopolymer-Based Delivery Systems: Challenges and Opportunities
Current Topics in Medicinal Chemistry Novel Oral Anticoagulants in the Management of Polycythemia Vera and Essential Thrombocythemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Progress in Medicinal Investigations on Trichosanthin and other Ribosome Inactivating Proteins from the Plant Genus Trichosanthes
Current Medicinal Chemistry Chromosome 3 Translocations and Familial Renal Cell Cancer
Current Molecular Medicine Malignant Mesothelioma: Biology, Diagnosis and Therapeutic Approaches
Current Molecular Pharmacology Glucose-6-phosphate Dehydrogenase: a Biomarker and Potential Therapeutic Target for Cancer
Anti-Cancer Agents in Medicinal Chemistry Circular RNAs and Glioma: Small Molecule with Big Actions
Current Molecular Medicine A Systematic Review of Genes Involved in the Inverse Resistance Relationship Between Cisplatin and Paclitaxel Chemotherapy: Role of BRCA1
Current Cancer Drug Targets Meet Our Editorial Board Member:
Current Organic Chemistry The Metabolic Fate of Apple Polyphenols in Humans
Current Nutrition & Food Science A Perspective on Clinical Islet Transplantation: Past, Present and Developments for Future
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Neurotoxins: Free Radical Mechanisms and Melatonin Protection
Current Neuropharmacology Determination of Dysregulated miRNA Expression Levels by qRT-PCR after the Application of Usnic Acid to Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Cyclooxygenase Enzymes: Regulation and Function
Current Pharmaceutical Design MicroRNA-31 Inhibits Lung Adenocarcinoma Stem-Like Cells via Down-Regulation of MET-PI3K-Akt Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Erlotinib: A Targeted Anticancer Drug
Current Cancer Therapy Reviews